Kintara Therapeutics to Present at the Emerging Growth Conference
Kintara Therapeutics, Inc. (Nasdaq: KTRA), a company that specializes in creating innovative treatments for solid tumor cancers, recently shared the exciting news that its President and CEO, Robert E. Hoffman, will be speaking at the Emerging Growth Conference on Wednesday, August 9, 2023, at 12:00 pm Eastern Time (ET).
For individuals investing who are keen on taking part, kindly utilize the provided hyperlink to sign up and stay informed about all conference-related information.
Situated in San Diego, California, Kintara is committed to creating innovative cancer treatments for individuals who are in need of medical solutions. Kintara is currently working on the advancement of two advanced therapies for specific medical conditions that have not been adequately addressed. These two initiatives consist of VAL-083, targeted towards glioblastoma (GBM), and REM-001 Therapy, developed for cutaneous metastatic breast cancer (CMBC).
VAL-083 is a new type of chemotherapy drug that works in a unique way and has been effective in treating various cancers, such as those in the central nervous system, ovaries, and other solid tumors like non-small cell lung cancer, bladder cancer, and head and neck cancer. These positive results were observed in clinical trials conducted by the National Cancer Institute (NCI). Building on the findings from both NCI-sponsored trials and our own research, Kintara is now moving forward with VAL-083 in a Phase 2/3 clinical trial called the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) Study. The goal of this trial is to gather more evidence to support the use and availability of VAL-083 for the treatment of glioblastoma, a type of brain cancer.
Kintara also has a unique, advanced method of treating tumors called photodynamic therapy. This therapy shows potential in treating tumors on the skin or internal organs, as well as other possible uses. REM-001 Therapy, which includes a laser light source, a device to deliver the light, and the REM-001 drug, has been tested in four clinical trials involving patients with CMBC who had already undergone chemotherapy and/or radiation therapy and experienced little progress. So far, REM-001 has shown clinical success in 80% of CMBC cases and has been proven safe in approximately 1,100 patients with various conditions.
If you want to know more, you can visit the website www.kintara.com or you can also find us on Twitter with the handle @Kintara_Thera, as well as on Facebook and LinkedIn.
This press release may contain statements that are forward-looking, meaning they discuss future events and expectations, as defined by the Private Securities Litigation Reform Act of 1995. These statements may include information about the progress of the Company's clinical trials and the GBM AGILE Study. While these forward-looking statements are based on current expectations, they are also subject to risks and uncertainties. These risks and uncertainties may cause actual results in the future to differ from current expectations. Some factors that could contribute to these differences include the Company's ability to develop, market, and sell products using its technology; the effectiveness and benefits of the Company's products and technology; the availability of sufficient funding to support the Company's operations, research and development, clinical studies, and product commercialization; the Company's business strategies and plans for research, product development, regulatory approval, marketing, and distribution; global unrest; and the ongoing impact of the COVID-19 pandemic. These factors and others are discussed in more detail in the Company's filings with the SEC, including its Annual Report on Form 10-K for the year ended June 30, 2022, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K.
Contact Mike Moyer, the Managing Director at InvestorsLifeSci Advisors, via phone at 617.308.4306 or email at [email protected].
Contact information for media inquiries: Name: David Schull or Ignacio Guerrero-Ros, Ph.D. Company: Russo Partners Phone: 858.717.2310 or 646.942.5604 Email: [email protected] or [email protected]
The emblem of Kintara Therapeutics (PRNewsfoto/Kintara Therapeutics)
Click on the provided link to access various forms of media, such as videos or images, available for download. This source, hosted by PR Newswire, announces Kintara Therapeutics' participation in the Emerging Growth Conference.
